Epidarex Portfolio News

EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY


Category: Epidarex Portfolio News

Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria

New designation now includes all PNH patients ​CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that the U.S. Food and…

Edinburgh Molecular Imaging Ltd Appoints New Chairman

Roy Davis appointed as Non-Executive Chairman. Current Chair John Jeans to continue as Non-Executive Director Edinburgh Molecular Imaging Ltd (EM Imaging), the clinical phase biotechnology company focused on enabling image-guided therapy, announces the appointment of Roy Davis as non-executive Chairman with immediate effect. John Jeans,…

NodThera Announces the Appointment of Alison Strutt PhD as Head of Finance & Operations, the Launch of its New Corporate Office in Boston and the Opening of its Laboratory in Seattle

Expansion in the US is consistent with NodThera’s strategy to access world class talent, foster collaborative relationships and develop deep insights into inflammasome biology to drive diversified chemistry into the clinic. Cambridge, UK, Boston, MA and Seattle, WA, 23rd October 2018. NodThera, a biotechnology company…